Lars Fruergaard Jørgensen 0.9 5 ideas

Novo Nordisk reported 7% organic growth but included "consumer softness" in North America in their guidance. While the company is executing well on integration and production, the explicit mention of consumer weakness suggests the "weight loss" trade is not immune to the broader economic slowdown. WATCH. Upside exists if the consumer is more resilient than their internal models predict. US pricing pressure or supply chain issues.

246,000 people are already on the Wegovy pill just five weeks after launch. The CEO is aggressively litigating against compounding pharmacies using unauthorized API. The shift from injection to oral delivery removes the biggest friction point for patients (needles), expanding the TAM (Total Addressable Market) significantly. Legal wins against compounders will restore pricing power and volume to the official product. Long NVO on the successful form-factor pivot. US government pressure on drug pricing.

"The pill starts with zero... we have 246,000 people after five weeks... 15 times better than when we launched Wegovy injection." + "90% of the people that are coming towards the pill are new patients." The market recently sold off NVO on fears of pricing pressure ("price cuts are happening on day one"). However, the CEO's data confirms that volume growth is massive and, crucially, the oral pill is expanding the Total Addressable Market (TAM) rather than cannibalizing existing injectable revenue. The volume ramp will likely offset pricing headwinds faster than Wall Street models expect. LONG NVO as the oral pill unlocks a new demographic of patients averse to injections. Supply constraints or faster-than-expected pricing degradation.

"Novo Nordisk in North Carolina makes the pill... from the scratch. Basically, the API is made in North Carolina... Many of our peers produce and have their API come from China." This is a "Geopolitical Alpha" play. With increasing US-China tensions (e.g., Biosecure Act, tariffs), pharmaceutical companies relying on Chinese API face significant supply chain risk. NVO's fully domestic US production for the oral pill creates a safety premium that peers lack. LONG NVO as a defensive play against US-China decoupling in the pharma supply chain. Manufacturing issues at the North Carolina plant.

"We saw Hims and Hers come out with basically a copycat... They since have scrapped that pill version... FDA came out and move pretty quickly against them." + "Lawsuit is around the Semaglutide IP as a whole... If anyone can bypass the FDA and simply put any product into the market, then the system is broken." HIMS has benefited from the shortage of branded GLP-1s by offering compounded alternatives. NVO is now explicitly targeting the "mass compounding" business model with legal force, and the FDA is aligning with big pharma. Even though HIMS scrapped the pill, NVO is pursuing the suit to protect the IP "as a whole," threatening the viability of HIMS's compounded GLP-1 revenue stream. SHORT HIMS due to existential legal and regulatory headwinds. HIMS successfully pivots to other verticals or the lawsuit is dismissed.